Roswell Park Cancer Institute (RPCI) is requesting support to continue its participation in Cancer and Leukemia Group B (CALGB). For the past 3 years, since the arrival of Dr. Bloomfield, interim funding has been secured to allow RPCI to develop its present role in the Group. The goals of the CALGB participation include: (i) increased accrual to phase II/phase III clinical trials, based upon a steadily increasing patient recruitment since the reorganization of clinical services at RPCI; a particular emphasis will be placed upon solid tumor oncology and new drug development; (ii) increased investigator participation in CALGB activities, consequent upon a major program of recruitment; (iii) increased scientific contribution, based upon the application of selected aspects of our rapidly evolving translational research program to CALGB; (iv) increased attention to minority groups with the development of specific multimodality clinics for patients with esophagus and prostate cancer. Founded in 1898, Roswell Park Cancer Institute (RPCI) was one of the first institutions dedicated exclusively to the research and treatment of cancer and allied diseases. With more than 1400 staff, 200 beds, a large outpatient facility, and nearly 1,000,000 square feet of laboratory and hospital space provided by the State of New York, RPCI constitutes one of the 3 largest Cancer Centers in the United States, and was one of the first NCI-designated Comprehensive Cancer Centers. Under the direction of a team of senior investigators with major track records in clinical trial design and methodology and multidisciplinary management, the staff at RPCI and affiliates have increased accrual to CALGB trials from only 31 cases in 1988 to 162 in 1991, with a projected accrual of 200 in 1992. Increasing accrual has been seen at both the Main institution and at the affiliates, with a particular increase recently in solid tumor recruitment. RPCI also contributes substantially to the scientific, administrative, core, and publication activities of CALGB, as evidenced by the 60 protocols currently or recently chaired by staff members; the presence of the Offices of the Correlative Science, Cytogenetics and Pathology Committees and Flow Cytometry Core Facilities; active participation in Core Committees; authorship on 84 CALGB publications since 1988; and the completion of many early phase/pilot studies that have given rise to subsequent CALGB protocols. With the development of a new marrow transplant program and a new commitment to multidisciplinary management of solid tumors (augmented by a further increase in the intramural level of translational research, e.g., the current development of an extensive program of interactive laboratory research between the Departments of Medicine, Surgery, Flow Cytometry, Pathology and the Grace Cancer Drug Center targeted on mechanisms of response and resistance to treatment), a new level of scientific leadership will be available to CALGB as Roswell Park Cancer Institute completes its first century of cancer research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Eisfeld, A-K; Mrózek, K; Kohlschmidt, J et al. (2017) The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia 31:2211-2218
Edelman, Martin J; Wang, Xiaofei; Hodgson, Lydia et al. (2017) Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol 35:2184-2192
Martin, Linda W; D'Cunha, Jonathan; Wang, Xiaofei et al. (2016) Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). J Clin Oncol 34:1484-91
DeBoer, Rebecca; Koval, Gregory; Mulkey, Flora et al. (2016) Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma 57:2298-306
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9

Showing the most recent 10 out of 58 publications